Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
If a commercial plan doesn't cover Mounjaro, the card can decrease the cost by up to $450 a month
The impact of GLP-1s extends beyond weight loss, with 2024 marking approvals for additional indications, namely major adverse cardiovascular events (MACE), sleep apnea, and metabolic dysfunction-associated steatohepatitis
Not catastrophic, but worth noting
Check the expiration date and storage conditions
It is most effective when used in conjunction with healthy eating habits and regular exercise
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
US$ 20.38
US$ 25.89
US$ 22.80
US$ 25.59
